Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ)

Renaissance Technologies LLC raised its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 300,400 shares of the company’s stock after purchasing an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned 0.85% of Equillium worth $208,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Acadian Asset Management LLC bought a new position in Equillium during the 1st quarter worth approximately $249,000. Institutional investors own 27.05% of the company’s stock.

Equillium Trading Up 2.1 %

EQ stock opened at $0.92 on Friday. The firm has a market cap of $32.59 million, a PE ratio of -3.68 and a beta of 1.83. Equillium, Inc. has a 1-year low of $0.45 and a 1-year high of $3.25. The stock has a 50-day moving average price of $0.87 and a 200-day moving average price of $1.13.

Equillium (NASDAQ:EQ) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.16. The firm had revenue of $13.85 million during the quarter, compared to analyst estimates of $8.15 million. Equillium had a negative return on equity of 36.88% and a negative net margin of 19.51%. On average, analysts forecast that Equillium, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Equillium in a research report on Monday, August 19th.

Insider Activity

In related news, insider Penny Tom sold 38,806 shares of Equillium stock in a transaction on Monday, September 16th. The shares were sold at an average price of $0.85, for a total value of $32,985.10. Following the sale, the insider now owns 10,051 shares in the company, valued at $8,543.35. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 58,806 shares of company stock worth $49,785 in the last three months. Corporate insiders own 30.30% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.